Please wait
Amgen Inc. (AMGN) is listed on the Nigerian Exchange in the Healthcare sector, with exposure to Drug Manufacturers - General. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
Healthcare
₦290T
2.8%
24.94
Current price
₦537,495.00
Updated Updated 36 min ago
Conviction
71/100
Confidence
Low
Market tone
neutral · 71/100
Entry
Medium · 71/100
Recent price action for AMGN, so the page starts with the stock itself before the deeper analysis.
This is a reasonably large name with enough regular flow that normal-sized exits should usually be workable.
Valuation view
Looks relatively cheap vs peers
Income view
Low income profile
Market tone
neutral (71/100) — price action, attention, and recent context all lean here.
Entry view
Medium (71/100) — The company is profitable on the latest reported numbers.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Investors usually follow AMGN for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Director dealings
0
Reported buys, sells, and mixed dealings.
Corporate actions
0
Dividend and company notices.
Market events
0
Insider, filing, dividend, and price events.
Source records
3
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 71/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
ROE
101.3%
Return on equity
ROA
8.3%
Return on assets
Debt / equity
6.24
Lower is usually safer.
P/B ratio
17.03
Useful for book value support.
Dividend yield
2.8%
Current income signal.
99/100
Direction
Positive bias
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Trading liquidity looks supportive for the forecast to transmit into price action.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦507,120.00
Analyst view
Buy
Analyst target
₦529,155.00
Forecast refresh
Updated 1h ago
Quality score
76
Growth score
55.21
These are the external analyst numbers and business outlook figures already synced into the company record.
Low target
₦55,650,000,000,000.00
High target
₦57,750,000,000,000.00
Revenue this year
₦56.7T
Revenue next year
₦58.1T
EPS this year
₦33,585.00
EPS next year
₦35,220.00
Dividend / share
₦10,560.00
Forward P/E
13.06
US stock catalog seed
Updated 2d ago
Seeded from the built-in US stock catalog for database discovery and later background refresh.
Price points saved
50
Latest market date
2026-06-26
Dividend yield
2.8%
Ex-dividend date
May 15, 2026
No sector spillover signal has been linked yet.
AMGN
Amgen Inc.
Price: ₦537,495.00
P/E: 24.94
Yield: 2.8%
ABBV
AbbVie Inc.
Price: ₦380,025.00
P/E: 124.8
Yield: 2.7%
ABT
Abbott Laboratories
Price: ₦141,180.00
P/E: 26.36
Yield: 2.7%
BMY
Bristol-Myers Squibb Company
Price: ₦86,280.00
P/E: N/A
Yield: N/A
Industry
Drug Manufacturers - General
Founded
1980
Employees
31,500
Exchange
NASDAQ
Ticker
AMGN
